March 15, 2023 Price forecast | 2 weeks: -2.94% | 1 month: -3.77% | 3 months: -18.23%


CMPX stock forecast

Our latest prediction for Compass Therapeutics Inc's stock price was made on the March 15, 2023 when the stock price was at 3.56$.

In the short term (2weeks), CMPX's stock price should underperform the market by -2.94%. During that period the price should oscillate between -8.72% and +5.46%.

In the medium term (3months), CMPX's stock price should underperform the market by -18.23%. During that period the price should oscillate between -26.51% and +16.68%.

Create a solid portfolio with CMPX

Add CMPX to your portfolio and optimize it!


About Compass Therapeutics Inc

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of None$ per share.

The book value per share is 1.33$

Compass Therapeutics Inc website


Three months stock forecastMarch 15, 2023


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -41M - -30M - - - 126M 1.33 - - -